Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies
Sign Up to like & getrecommendations! Published in 2019 at "Osteoporosis International"
DOI: 10.1007/s00198-019-04968-x
Abstract: SummaryIn the present meta-analysis based on real-world data, the use of dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonists (GLP-1ra), or sodium-glucose cotransporter-2 inhibitors (SGLT2i) was not associated with the risk of fracture.IntroductionCumulative evidence from… read more here.
Keywords: real world; risk; glp 1ra; use ... See more keywords
Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes Therapy"
DOI: 10.1007/s13300-021-01012-2
Abstract: The aim of this study was to elaborate a consensus on treatment intensification strategies in patients with type 2 diabetes failing basal insulin supported oral therapy (BOT). The panel focused on glucagon-like peptide-1 receptor agonists… read more here.
Keywords: insulin; glp 1ra; bot; treatment ... See more keywords
Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical therapeutics"
DOI: 10.1016/j.clinthera.2021.03.003
Abstract: PURPOSE Patients managing type 2 diabetes mellitus (T2DM) often require combination therapy to meet their blood glucose control targets. With limited real-world evidence focused on the use of glucagon-like peptide 1 receptor agonist (GLP-1RA) therapies,… read more here.
Keywords: mmol; real world; glp 1ra; a1c ... See more keywords
Cardio-renal outcomes and the direct medical cost of type 2 diabetes patients treated with sodium glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based cohort study.
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes research and clinical practice"
DOI: 10.1016/j.diabres.2021.109071
Abstract: AIMS To compare cardio-renal outcomes and incurred direct medical costs of patients initiating sodium glucose cotransporter-2 inhibitors (SGLT2i) versus glucagon-like peptide-1 receptor agonists (GLP-1RA). METHODS A population-based cohort of patients with type 2 diabetes was… read more here.
Keywords: glp 1ra; sodium glucose; cardio renal; direct medical ... See more keywords
Glucagon-like peptide-1 receptor agonist attenuates diabetic neuropathic pain via inhibition of NOD-like receptor protein 3 inflammasome in brain microglia.
Sign Up to like & getrecommendations! Published in 2022 at "Diabetes research and clinical practice"
DOI: 10.1016/j.diabres.2022.109806
Abstract: AIMS We aimed to explore the evidence of brain microglia activation in diabetic neuropathic pain (DNP) and the effect and mechanism of glucagon-like peptide-1 receptor agonist (GLP-RA) on DNP via brain microglia. METHODS Brain microglia… read more here.
Keywords: brain microglia; dnp rats; glp 1ra; brain ... See more keywords
Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of diabetes and its complications"
DOI: 10.1016/j.jdiacomp.2016.08.018
Abstract: Incretin based therapies such as dipeptidyl peptidase-4 inhibitors (DPP-4i) and glucagon-like peptide-1 receptor agonists (GLP-1Ra) are increasingly used for the treatment of Type 2 diabetes mellitus. In clinical practice and in previously performed clinical trials,… read more here.
Keywords: therapy; type diabetes; glp 1ra; incretin based ... See more keywords
Cardiovascular benefits of GLP-1RA and SGLT-2i in women with type 2 diabetes.
Sign Up to like & getrecommendations! Published in 2022 at "Primary care diabetes"
DOI: 10.1016/j.pcd.2022.03.012
Abstract: Given the CV benefit noted in the CVOTs, GLP-1RAs and SGLT-2is are given preference in T2DM guidelines. While guidelines do not report potential gender difference, those differences exist. On restricting the CVOTs results to women… read more here.
Keywords: diabetes cardiovascular; sglt women; glp 1ra; 1ra sglt ... See more keywords
The role of Recent Pharmacotherapeutic Options on the Management of Treatment Resistant Type 2 Diabetes
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2022.2089021
Abstract: ABSTRACT Introduction Type 2 diabetes mellitus is a complex progressive disease leading to chronic hyperglycemia due to insulin resistance and pancreatic beta-cell failure. Intensification of treatment regimens is often necessary due to the overall decline… read more here.
Keywords: glp 1ra; treatment resistant; type diabetes; treatment ... See more keywords
The correlations between steady-state concentration, duration of action and molecular weight of GLP-1RAs and their efficacy and gastrointestinal side effects in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2023 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2023.2181693
Abstract: ABSTRACT Background To assess the influence of steady-state concentration, duration of action and molecular weight of glucagon-like peptide-1 receptor (GLP-1RA) on efficacy and gastrointestinal (GI) side effects in patients with type 2 diabetes mellitus (T2DM).… read more here.
Keywords: steady state; state concentration; stratum; glp 1ra ... See more keywords
A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment
Sign Up to like & getrecommendations! Published in 2018 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2018.1428305
Abstract: ABSTRACT Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium glucose cotransporter 2 inhibitors (SGLT2i) are of particular interest in type 2 diabetes treatment strategies, due to their efficacy in reducing HbA1c with a low risk… read more here.
Keywords: diabetes treatment; glp 1ra; safety; receptor agonists ... See more keywords
Glucagon like peptide-1 receptor agonists and their combination with sodium-glucose cotransporter-2 inhibitors improve myocardial deformation and work index in type-2 diabetes after 12-month treatment
Sign Up to like & getrecommendations! Published in 2020 at "European Heart Journal"
DOI: 10.1093/ehjci/ehaa946.0115
Abstract: Type-2 diabetes mellitus (T2DM) exacerbates mechanisms of atherosclerosis and heart failure. We investigated the effects of insulin, glucagon like peptide-1 receptor agonists (GLP-1RA), sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and their combination on LV myocardial function of… read more here.
Keywords: combination; work; glp 1ra; treatment ... See more keywords